Spikevax, Moderna’s mRNA-based COVID-19 vaccine, remains the company’s flagship commercial product as updated formulations target circulating variants and support ongoing global booster campaigns.
Three new, fast-spreading variants of the virus that causes COVID-19 can evade antibodies that work against the original form that sparked the pandemic, new research shows. With few exceptions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results